nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT03739827,Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors,,Recruiting,Observational,Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor,,,National Cancer Institute (NCI),,10000,2019-01-28,2032-03-31,United States,No,https://clinicaltrials.gov/study/NCT03739827
NCT03812653,Sleep for Stroke Management and Recovery Trial,Not Applicable,Recruiting,Interventional,"Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial",CPAP,,University of Michigan,National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati,3062,2019-05-09,2026-11-05,United States,No,https://clinicaltrials.gov/study/NCT03812653
NCT04256018,"A Phase 2 Single Center, Single Arm, Open Label Mogamulizumab Combined Upfront With Low Dose Total Skin Electron Beam Therapy (LD TSEBT) in Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS)",Phase 2,Recruiting,Interventional,Sezary Syndrome; Mycosis Fungoides,Mogamulizumab; LD TSEBT,,Stanford University,,30,2020-03-30,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT04256018
NCT04458584,Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART),,Recruiting,Observational,Osteoarthritis Thumb,Trapeziectomy with ligament reconstruction (I; LRTI); Trapeziectomy with suture suspensionplasty (II; SS); Arthroscopic Trapeziectomy (III; AT),,Dartmouth-Hitchcock Medical Center,,165,2020-06-29,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04458584
NCT04471727,"A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).",Phase 1/Phase 2,Recruiting,Interventional,Small-Cell Lung Cancer; Neuroendocrine Carcinoma,Gocatamig; Atezolizumab; Ifinatamab Deruxtecan (I-DXd),,"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Daiichi Sankyo,232,2020-12-14,2027-11-03,United States,No,https://clinicaltrials.gov/study/NCT04471727
NCT04606446,"A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS",Phase 1,Recruiting,Interventional,Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer,"PF-07248144; Fulvestrant; Letrozole; Palbociclib; PF-07220060; PF-07850327, ARV-471, vepdegestrant",,Pfizer,,320,2020-11-16,2029-09-22,Australia; China; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04606446
NCT04995003,Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0),Phase 1,Recruiting,Interventional,Sarcoma; HER-2 Protein Overexpression; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma; Synovial Sarcoma; Soft Tissue Sarcoma; Undifferentiated Sarcoma,T cells or CAR T cells; Pembrolizumab Injectable Product; Nivolumab Injectable Product,,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation; National Cancer Institute (NCI)",25,2021-12-07,2040-12-31,United States,No,https://clinicaltrials.gov/study/NCT04995003
NCT05068583,Liquid Biopsies in Non-CNS Malignant Pediatric Solid Tumors,,Recruiting,Observational,"Pediatric Solid Tumor, Unspecified, Protocol Specific",Blood Draw,,Children's Hospital Los Angeles,,320,2019-05-08,2034-05-08,United States,No,https://clinicaltrials.gov/study/NCT05068583
NCT05100862,"A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",Phase 3,Recruiting,Interventional,Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma,Zanubrutinib; Rituximab; Lenalidomide; Obinutuzumab,,BeiGene,,780,2022-03-10,2030-06-05,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; France; Georgia; Germany; Greece; Ireland; Israel; Italy; Japan; Poland; Portugal; Puerto Rico; Romania; South Africa; South Korea; Spain; Switzerland; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05100862
NCT05103046,"A Phase 1, First in Human, Dose-Escalation Study of UCT-03-008 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor,UCT-03-008,,"1200 Pharma, LLC",Translational Research in Oncology,68,2021-12-23,2025-12-15,United States,No,https://clinicaltrials.gov/study/NCT05103046
NCT05227326,First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors,Phase 1,Recruiting,Interventional,Refractory Malignant Solid Neoplasm; Osteosarcoma; Leiomyosarcomas; Synovial Sarcomas; Ovarian Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer,PCNA Inhibitor AOH1996,,City of Hope Medical Center,National Cancer Institute (NCI),92,2022-08-12,2029-09-13,United States,No,https://clinicaltrials.gov/study/NCT05227326
NCT05265273,"An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis",Phase 2/Phase 3,Recruiting,Interventional,Myasthenia Gravis,Nipocalimab,,"Janssen Research & Development, LLC",,12,2022-07-20,2026-06-26,Japan; Netherlands; Poland; United States,No,https://clinicaltrials.gov/study/NCT05265273
NCT05385965,Meaning-Centered Pain Coping Skills Training: A Randomized Controlled Trial of a Psychosocial Intervention for Advanced Cancer Patients,Not Applicable,Recruiting,Interventional,Advanced Solid Tumor; Pain,Meaning-Centered Pain Coping Skills Training,,Duke University,"American Cancer Society, Inc.",210,2023-02-09,2026-03-26,United States,No,https://clinicaltrials.gov/study/NCT05385965
NCT05582993,"A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease",Phase 3,Recruiting,Interventional,Von Willebrand Disease (VWD),Vonicog Alfa; ADVATE,,Takeda,,24,2024-11-06,2030-04-11,France; Ireland; Italy; Japan; United States,No,https://clinicaltrials.gov/study/NCT05582993
NCT05642455,"A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors",Phase 1/Phase 2,Recruiting,Interventional,Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcoma,Afamitresgene autoleucel,,Adaptimmune,,20,2023-09-01,2038-07-30,United States,No,https://clinicaltrials.gov/study/NCT05642455
NCT05651945,Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors,Not Applicable,Recruiting,Interventional,Stroke; Cerebrovascular Accident,Cardiac rehabilitation program,,Hackensack Meridian Health,The Cardiovascular Institute of New Jersey at Rutgers Robert Wood Johnson Medical School,150,2023-01-20,2031-01-20,United States,No,https://clinicaltrials.gov/study/NCT05651945
NCT05661461,"A Phase 1, Open-label, Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment",Phase 1,Recruiting,Interventional,"Tumor, Solid; Tumor; Advanced Solid Tumor",nab-sirolimus,,"Aadi Bioscience, Inc.",,28,2022-11-23,2026-08-01,United States,No,https://clinicaltrials.gov/study/NCT05661461
NCT05696691,A Randomized Pilot Trial of Intramuscular Ketamine and Crisis Response Planning for Suicide Prevention in the Emergency Department,Phase 2/Phase 3,Recruiting,Interventional,Suicide,Ketamine Hydrochloride; Crisis Response Plan,,The University of Texas Health Science Center at San Antonio,National Center for Advancing Translational Sciences (NCATS),24,2023-01-06,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05696691
NCT05711615,A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas,Phase 1,Recruiting,Interventional,Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Pegylated Liposomal Doxorubicin Hydrochloride; Peposertib,,National Cancer Institute (NCI),,30,2024-02-06,2026-05-03,United States,No,https://clinicaltrials.gov/study/NCT05711615
NCT05730036,"An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)",Phase 3,Recruiting,Interventional,Relapsed Refractory Multiple Myeloma (RRMM),Linvoseltamab; Elotuzumab; Pomalidomide; Dexamethasone,,Regeneron Pharmaceuticals,,410,2023-09-18,2033-04-19,Australia; Belgium; Brazil; Canada; Chile; France; Germany; Israel; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05730036
NCT05910307,Synovial Sarcoma Registry and Biospecimen Repository,,Recruiting,Observational,Synovial Sarcoma,,,Children's Hospital of Philadelphia,,1000,2023-06-12,2033-06-05,United States,No,https://clinicaltrials.gov/study/NCT05910307
NCT05941039,Effects of Vestibular Training on Postural Control of Healthy Adults Using Virtual Reality,Not Applicable,Recruiting,Interventional,Virtual Reality; Vestibular Training; Balance Assessment,Vestibular training using VR followed by Control; Control followed by Vestibular training using VR,,Clarkson University,Temple University,30,2022-10-03,2025-08-30,United States,No,https://clinicaltrials.gov/study/NCT05941039
NCT05965245,Suubi-Mhealth: A Mobile Health Intervention to Address Depression and Improve ART Adherence Among Youth Living With HIV (YLHIV) in Uganda,Not Applicable,Recruiting,Interventional,Depression; HIV Infection,Suubi-Mhealth,,Washington University School of Medicine,National Institute of Mental Health (NIMH),278,2022-11-23,2027-08-31,Uganda; United States,No,https://clinicaltrials.gov/study/NCT05965245
NCT05999994,CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research,Phase 2,Recruiting,Interventional,Neoplasms; Child; Adolescent,Ramucirumab; Cyclophosphamide; Vinorelbine; Gemcitabine; Docetaxel; Abemaciclib; Irinotecan; Temozolomide,,Eli Lilly and Company,,105,2020-01-22,2027-05-05,Australia; Belgium; France; Germany; Italy; Japan; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05999994
NCT06083883,Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma,Phase 1,Recruiting,Interventional,Synovial Sarcoma; Myxoid/Round Cell Liposarcoma,Fludarabine phosphate; NY-ESO-1 TCR/IL-15 NK; Cyclophosphamide,,M.D. Anderson Cancer Center,,44,2024-03-27,2028-11-30,United States,No,https://clinicaltrials.gov/study/NCT06083883
NCT06096597,"Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-Blind, Randomized Controlled Trial",Phase 2/Phase 3,Recruiting,Interventional,Interstitial Cystitis; Painful Bladder Syndrome; Painful Bladder Syndrome (PBS),Clarix Flo; Placebo,,David Sheyn,,100,2024-07-24,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06096597
NCT06187402,"A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,LM-24C5,,LaNova Medicines Limited,,49,2023-12-20,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT06187402
NCT06208150,"A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",Phase 3,Recruiting,Interventional,Multiple Myeloma,Talquetamab; Pomalidomide; Teclistamab; Elotuzumab; Dexamethasone; Bortezomib,,"Janssen Research & Development, LLC",,795,2024-01-22,2028-03-31,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Poland; Saudi Arabia; South Korea; Spain; Sweden; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06208150
NCT06216301,"LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer,NovoTTF-200T; Pembrolizumab; Platinum based chemotherapy,,NovoCure GmbH,,734,2024-07-31,2028-10-05,Austria; Belgium; Czechia; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Singapore; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06216301
NCT06225804,"A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,ABSK112,,"Abbisko Therapeutics Co, Ltd",,164,2024-02-22,2028-03-05,China; United States,No,https://clinicaltrials.gov/study/NCT06225804
NCT06290128,"A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy",Phase 3,Recruiting,Interventional,"Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinating, Chronic",Riliprubart; Placebo; Riliprubart; Placebo,,Sanofi,,140,2024-07-12,2028-11-20,Argentina; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; France; Germany; Greece; Italy; Japan; Mexico; Netherlands; Poland; Portugal; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06290128
NCT06290141,"A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy",Phase 3,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyneuropathy,riliprubart; Placebo; riliprubart; Placebo; IVIg; Placebo,,Sanofi,,160,2024-08-21,2029-01-12,Argentina; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Hungary; Israel; Japan; Mexico; Portugal; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06290141
NCT06351631,"A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study",Phase 3,Recruiting,Interventional,"Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera",Bomedemstat,,Merck Sharp & Dohme LLC,,400,2024-05-23,2034-12-04,Australia; Hong Kong; Italy; New Zealand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06351631
NCT06447168,"Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg/Day in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting.",,Recruiting,Observational,Primary Biliary Cholangitis,,,Ipsen,,424,2024-10-14,2032-07-15,Austria; Canada; Germany; Greece; Italy; United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06447168
NCT06524635,A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis,Phase 2,Recruiting,Interventional,Hidradenitis Suppurativa; Atopic Dermatitis,Lutikizumab,,AbbVie,,60,2024-08-14,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT06524635
NCT06625190,"Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Neuroblastoma; Rhabdomyosarcoma; Synovial Sarcoma; Peripheral Nerve Sheath Tumors; Clear Cell Sarcoma; Alveolar Soft Part Sarcoma; Desmoplastic Small Round Cell Tumor; Chordoma; Rhabdoid Tumor; Epithelioid Sarcoma; Myoepithelial Tumor; Osteosarcoma; Ewing Sarcoma,Miltenyi CliniMACS Prodigy ® system; Zoledronic acid,,University of Florida,,27,2026-02-05,2030-02-05,United States,No,https://clinicaltrials.gov/study/NCT06625190
NCT06644755,"Phase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors; Sarcoma,DS-2243a,,Daiichi Sankyo,,150,2024-11-14,2028-11-30,Belgium; France; Netherlands; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06644755
NCT06689891,"Utilizing Remote, Video-Based Pelvic Floor Muscle Therapy: A Feasibility Trial",Not Applicable,Recruiting,Interventional,Pelvic Floor Disorder; Pelvic Floor Muscle Exercise,Pelvic Floor Muscle Therapy Website,,Yale University,,20,2025-06-09,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06689891
NCT06713473,Reducing Self-Dehumanization to Examine the Effects on Oxytocin and Suicide Risk,Not Applicable,Not yet recruiting,Interventional,Rehumanization Intervention; Control Intervention,Rehumanized Intervention; Control Intervention; Clinical Interview; Self-Report Measures; Blood Draw,,Florida State University,,50,2026-08-05,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06713473
NCT06727097,Tracking the Development and Influence of Post-Stroke Sensory Reweighting on Walking and Balance Outcomes,,Recruiting,Observational,Ischemic Stroke,Posturography; Walking Speed; Instrumented 7M Timed UP and GO; Fall Event Records; MRI (3T),,University of Cincinnati,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),45,2024-11-01,2026-08-30,United States,No,https://clinicaltrials.gov/study/NCT06727097
NCT06736171,Prescription of Robotic Exoskeletons for Ambulation Recovery Post Stroke,Not Applicable,Recruiting,Interventional,Hemiparesis After Stroke,Robotic Exoskeleton; SOC,,Kessler Foundation,,96,2025-05-15,2030-06-05,United States,No,https://clinicaltrials.gov/study/NCT06736171
NCT06747351,"A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy",Phase 3,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP),TAK-881; HYQVIA; SC Investigational Needle Sets,,Takeda,"Takeda Development Center Americas, Inc.",59,2025-05-06,2028-06-25,Argentina; Czechia; Denmark; Germany; Greece; Italy; Japan; Poland; Spain; Sweden; United States,No,https://clinicaltrials.gov/study/NCT06747351
NCT06748872,"EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a",Phase 1,Not yet recruiting,Interventional,Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer; Soft Tissue Sarcoma (STS); Myxoid Liposarcoma; Synovial Sarcoma,Lymphodepletion; TCR-T cells (MDG1015),,Medigene AG,,55,2025-07-01,2042-08-01,United States,No,https://clinicaltrials.gov/study/NCT06748872
NCT06752668,"A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)",Phase 2,Recruiting,Interventional,Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia,ORX750; Placebo,,Centessa Pharmaceuticals (UK) Limited,,96,2024-12-23,2025-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT06752668
NCT06795659,Combining Esketamine and Prolonged Exposure for PTSD: A Proof-of-Concept Clinical Trial,Phase 1/Phase 2,Recruiting,Interventional,Post Traumatic Stress Disorder PTSD,Esketamine (Intranasal Spray); Massed Prolonged Exposure (PE),,The University of Texas Health Science Center at San Antonio,Institute for Integration of Medicine & Science-UT Health San Antonio,8,2025-06-09,2025-12-30,United States,No,https://clinicaltrials.gov/study/NCT06795659
NCT06799702,"Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South",Not Applicable,Not yet recruiting,Interventional,HIV Pre-exposure Prophylaxis; HEPATITIS C (HCV); Opioid Use Disorder,Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID),,University of Georgia,National Institute on Drug Abuse (NIDA),50,2026-08-01,2028-07-31,United States,No,https://clinicaltrials.gov/study/NCT06799702
NCT06832618,"A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis",Phase 3,Recruiting,Interventional,Atopic Dermatitis,Ruxolitinib; Vehicle Cream,,Incyte Corporation,,240,2025-06-17,2028-05-18,Belgium; Canada; France; Germany; Hungary; Italy; Netherlands; Poland; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06832618
NCT06858579,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)",Phase 3,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyneuropathy,DNTH103; DNTH103; Placebo,,Dianthus Therapeutics,,480,2025-02-10,2030-12-31,Argentina; Australia; Brazil; Bulgaria; China; Denmark; France; Georgia; Germany; Italy; Latvia; Malaysia; Netherlands; Poland; Romania; Serbia; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06858579
NCT06859099,Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Phase 3,Enrolling by invitation,Interventional,"Polyneuropathy, Inflammatory Demyelinating, Chronic",Riliprubart Prefilled Pen (PFP),,Sanofi,,300,2025-04-01,2029-10-03,Canada; Chile; China; Czechia; Denmark; France; Germany; Italy; Netherlands; Poland; Serbia; South Korea; Spain; Sweden; United States,No,https://clinicaltrials.gov/study/NCT06859099
NCT06890884,"A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)",Phase 2,Recruiting,Interventional,"Lymphoma, Large B-Cell, Diffuse",Zilovertamab vedotin; Rituximab; Cyclophosphamide; Doxorubicin; Rituximab Biosimilar; Prednisone; Prednisolone; Polatuzumab vedotin; Rescue Medication,,Merck Sharp & Dohme LLC,,594,2025-04-11,2032-12-16,Belgium; Germany; Ireland; Israel; Italy; Japan; Poland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06890884
NCT06900712,"A Novel, Single-Session Intervention for Sexual Assault-Related Psychopathology Among College Students",Not Applicable,Recruiting,Interventional,PTSD; Depression,PATH-SS,,Case Western Reserve University,,45,2025-07-17,2026-05-31,United States,No,https://clinicaltrials.gov/study/NCT06900712
NCT06920004,"A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy",Phase 3,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; CIDP - Chronic Inflammatory Demyelinating Polyneuropathy,empasiprubart; IVIg; empasiprubart-placebo; IVIg-placebo,,argenx,,218,2025-08-22,2030-09-05,United States,No,https://clinicaltrials.gov/study/NCT06920004
NCT06946225,"A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)",Phase 1,Recruiting,Interventional,Cutaneous Melanoma; Synovial Sarcoma,IMA203; mRNA-4203,,"Immatics US, Inc.","ModernaTX, Inc.",15,2025-07-25,2029-08-05,United States,No,https://clinicaltrials.gov/study/NCT06946225
NCT06970301,"A Single-center, Placebo-controlled, Participant-blind, Investigator-blind, Randomized, Multiple Ascending Dose in Titration Study to Assess The Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants",Phase 1,Recruiting,Interventional,Healthy Study Participants,glovadalen; Placebo,,UCB Biopharma SRL,,32,2025-04-28,2026-05-04,United States,No,https://clinicaltrials.gov/study/NCT06970301
NCT06972459,A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes,Phase 3,Recruiting,Interventional,Obesity; Overweight,Orforglipron; Placebo,,Eli Lilly and Company,,600,2025-05-15,2027-08-05,Argentina; China; Czechia; Germany; Japan; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06972459
NCT07032272,"A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Remibrutinib (LOU064) in Participants With Severe Renal Impairment Compared to Matched Healthy Participants With Normal Renal Function",Phase 1,Recruiting,Interventional,Autoimmune and Chronic Inflammatory Diseases,remibrutinib,,Novartis Pharmaceuticals,,16,2025-07-23,2025-11-24,United States,No,https://clinicaltrials.gov/study/NCT07032272
NCT07064473,"A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease",Phase 3,Recruiting,Interventional,"Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases",Vicadrostat; Empagliflozin; Placebo matching Vicadrostat,,Boehringer Ingelheim,,11800,2025-07-22,2029-12-21,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Portugal; Puerto Rico; Romania; Saudi Arabia; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT07064473
NCT07221240,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects",Phase 1,Recruiting,Interventional,Amyotrophic Lateral Sclerosis,Amisodin; Placebo,,"PRG Science & Technology Co., Ltd.",,32,2025-10-01,2026-07-03,United States,No,https://clinicaltrials.gov/study/NCT07221240
NCT07225296,"A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose, and Food-effect Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GNS-3545 in Healthy Adult Subjects",Phase 1,Recruiting,Interventional,Idiopathic Pulmonary Fibrosis,GNS-3545; GNS-3545 Placebo,,Genosco Inc.,,72,2025-11-12,2026-10-31,United States,No,https://clinicaltrials.gov/study/NCT07225296
NCT07261657,A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy,Early Phase 1,Not yet recruiting,Interventional,Myxoid Liposarcoma; Round Cell Liposarcoma; Synovial Sarcoma,Biospecimen Collection; Computed Tomography; Leukapheresis; Magnetic Resonance Imaging; Nogapendekin Alfa Inbakicept; X-Ray Imaging,,Northwestern University,National Cancer Institute (NCI),8,2026-09-02,2032-09-02,United States,No,https://clinicaltrials.gov/study/NCT07261657
NCT07282600,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes",Phase 3,Recruiting,Interventional,Overweight; Obesity,Eloralintide; Placebo,,Eli Lilly and Company,,1035,2025-12-15,2028-02-05,Argentina; China; Czechia; Germany; India; Japan; Mexico; Poland; Puerto Rico; Slovakia; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT07282600
NCT07286383,Testing the Use of VA Peer Specialists to Prevent Veteran Suicide,Phase 3,Not yet recruiting,Interventional,Suicide Risk,PREVAIL,,VA Office of Research and Development,,306,2026-04-01,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT07286383
